Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Growth of Cancer Development
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: AT a Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Life Expectancy and Cancer
- Description of Cancers
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
- Overview
- Product Descriptions and Examples
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
- Overview
- Product Descriptions and Examples
- Corticosteroids
- Synthetic Corticosteroids
- Hormone Agonists and Antagonists
- Estrogens
- Androgens
- Antiestrogens
- Antiandrogens
- Gonadotropin-releasing Hormone Analogues
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS
- Overview
- Product Descriptions and Examples
- Monoclonal Antibodies
- Avastin (bevacizumab)
- Campath (alemtuzumab)
- Erbitux (cetuximab)
- Herceptin (trastuzumab)
- Mylotarg (gemtuzumab ozogamicin)
- Panorex (edrecolomab)
- Rituxan (rituximab)
- Vectibix (panitumumab)
- Interleukins/Interferons
- Alferon-N
- Infergen
- Intron A
- Proleukin
- Roferon A
- Other Biotherapy
- Antisense Oligonucleotides
- Apoptosis
- Growth Factors
- Methylation
- P53
- Ras Protein Drugs
- Regulatory Enzymes
- Proteasome Inhibitors
- Radioimmunotherapy
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Overview
- Total Market Size and Forecast
- Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Introduction
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol' s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Possibility for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends
- United States
- Europe
- Japan
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
CHAPTER EIGHT: CORPORATE PROFILES
- Introduction
- AstraZeneca plc
- Biogen IDEC, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Genentech, Inc.
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Schering-Plough Corporation
CHAPTER NINE: COMPANY DIRECTORY
LIST OF EXHIBITS
EXECUTIVE SUMMARY
- Table 1-1 World Cancer Treatment Market, 2004-2013
- Figure 1-1 World Cancer Treatment Market, 2004-2013
INTRODUCTION
- Table 2-1 Viruses Associated with Cancer in Humans
- Table 2-2 Cancer Therapy Approvals per Year in the United States, 1970-2008
- Figure 2-1 Cancer Therapy Approvals per Year in the United States,
1970-2008
- Table 2-3 Estimated and Projected World Cancer Incidence by Selected Types
of Cancer, 2007 and 2020
- Figure 2-2 Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2007 and 2020
- Table 2-4 Cancer Incidence and Mortality by Country 2007
- Figure 2-3 Cancer Incidence by Country 2007
- Figure 2-4 Cancer Deaths by Country 2007
- Table 2-5 Total Cancer Incidence by Sex and Country, 2007
- Figure 2-5 Total Cancer Incidence by Sex and Country, 2007
- Table 2-6 World Population by Selected Geographical Region, 2007 - 2050
- Figure 2-6 World Population by Selected Geographical Region, 2007-2050
- Table 2-7 Estimated World Population by Age and Geographical Region, 2007
- Figure 2-7 Estimated World Population by Age and Geographical Region, 2007
- Table 2-8 Percent Population Over 65 by Year and Region
- Figure 2-8 Estimated World Population by Age, 2007 and 2050
- Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008
- Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008
- Table 2-10 United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2004
- Table 2-11 United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2004
- Figure 2-12 Approved Cancer Therapies in the United States by Indication
- Table 2-10 Types Of Leukemia
- Table 2-11 Types Of Primary Lung Cancer
- Table 2-12 Classification Of Non-hodgkin' s Lymphomas
- Table 2-13 Malignant Conditions Of The Skin
CHEMOTHERAPY
- Table 3-1 Leading Products, 2008
- Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved
Indications, 2007 through 2009
- Table 3-3 World Chemotherapy Market, 2004-2013
- Figure 3-1 World Chemotherapy Market, 2004-2013
- Table 3-4 World Chemotherapy Market, Market by Product Classification,
2004-2013
- Figure 3-2 World Chemotherapy Market
- Figure 3-3 World Chemotherapy Market
- Figure 3-4 World Chemotherapy Market
- Figure 3-5 World Chemotherapy Market
- Figure 3-6 World Chemotherapy Market
- Figure 3-7 World Chemotherapy Market
- Table 3-5 World Chemotherapy Market
- Figure 3-8 World Chemotherapy Market
- Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market
Revenues, 2008
- Figure 3-9 World Chemotherapy Market, Leading Suppliers Market Share, 2008
HORMONE THERAPY
- Table 4-1 Leading Products, 2008
- Table 4-2 Newly Approved Hormone Cancer Therapies and Additional
Indications 2007 through 2009
- Table 4-3 World Hormone Therapy Market, 2004-2013
- Figure 4-1 World Hormone Therapy Market, 2004-2013
- Table 4-4 World Hormone Therapy Market, Market by Product Classification,
2004-2013
- Figure 4-2 World Hormone Therapy Market, Market by Product Classification
Revenues, 2004-2013
- Figure 4-3 World Hormone Therapy Market, Market by Product Classification
and Percent Distribution, 2004-2013
- Figure 4-4 World Hormone Therapy Market, Market by Product Classification
and Percent Market Share, 2008
- Figure 4-5 World Hormone Therapy Market, Market by Product Classification
and Percent Market Share, 2013
- Figure 4-5 World Hormone Therapy Market
- Figure 4-6 World Hormone Therapy Market
- Table 4-6 World Hormone Therapy Market
- Figure 4-7 World Hormone Therapy Market
- Table 4-7 World Hormone Therapy Market, Leading Suppliers Shares by Market
Revenues, 2008
- Figure 4-8 World Hormone Therapy Market, Leading Suppliers Market Share,
2008
BIOTHERAPEUTICS
- Table 5-1 Leading Products, 2008
- Table 5-2 Newly Approved Biological Therapies and Additional Indications,
2007 through March 2009
- Table 5-3 World Cancer Biotherapeutics Market, 2004-2013
- Figure 5-1 World Cancer Biotherapeutics Market, 2004-2013
- Table 5-4 World Cancer Biotherapeutics Market Market by Product Type,
(Monoclonal Antibodies, Interleukins/ Interferons, Other) 2004-2013
- Figure 5-2 World Cancer Biotherapeutics Market, Market by Product
Classification (Monoclonal Antibodies, Interleukins/ Interferons, Other)
OtherRevenues, 2004-2013
- Figure 5-3 World Cancer Biotherapeutics Market, Market by Product
Classification and Percent Distribution, 2004-2013
- Figure 5-4 World Cancer Biotherapeutics Market, Market by Product
Classification and Percent Market Share, 2008
- Figure 5-5 World Cancer Biotherapeutics Market, Market by Product
Classification and Percent Market Share, 2013
- Figure 5-6 World Cancer Biotherapeutics Market
- Figure 5-7 World Cancer Biotherapeutics Market
- Table 5-5 World Cancer Biotherapeutics Market
- Figure 5-8 World Cancer Biotherapeutics Market
- Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market
Revenues, 2008
- Figure 5-9 World Cancer Biotherapeutics Market, Leading Suppliers Market
Share, 2008
WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Table 6-1 World Cancer Market Market by Product Type, 2004-2013
- Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2004-2013
- Figure 6-2 World Cancer Market, Market by Product Type and Percent
Distribution, 2004-2013
- Figure 6-3 World Cancer Market, Market by Product Type and Percent Market
Share, 2008
- Figure 6-4 World Cancer Market, Market by Product Type and Percent Market
Share, 2013
- Table 6-2 World Cancer Market, Top Five Suppliers Shares by Market
Revenues, 2008
- Figure 6-5 World Cancer Market, Top Five Suppliers Market Share, 2008
Issues and Trends Affecting the Cancer Market
ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Table 7-1 Obesity Rates by State
- Table 7-2 Select Products in Development by Product Name
- Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications
ORPORATE PROFILES
- Figure 8-1 Late stage Cancer Therapies in Development for Leading Companies
|
Related Report
|
View Cart
